1,028 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Merck's Keytruda Could Face Direct Competition from New Chinese Drug https://www.fool.com/investing/2020/01/21/mercks-keytruda-could-face-direct-competition-from.aspx?source=iedfolrf0000001 Jan 21, 2020 - Chinese drugmaker BeiGene would compete directly with Merck's cancer superdrug.
AstraZeneca and Merck Get an FDA Priority Review for Lynparza in Prostate Cancer https://www.fool.com/investing/2020/01/21/astrazeneca-and-merck-get-an-fda-priority-review-f.aspx?source=iedfolrf0000001 Jan 21, 2020 - The blockbuster drug is already approved for three other types of tumors.
Is Merck & Co. (MRK) a Profitable Pick for Value Investors? http://www.zacks.com/stock/news/726509/is-merck-co-mrk-a-profitable-pick-for-value-investors?cid=CS-ZC-FT-analyst_blog|value_stocks-726509 Jan 20, 2020 - Merck & Co. (MRK) stock may be a good choice for value-oriented investors right now from multiple angles.
Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat? http://www.zacks.com/stock/news/722277/will-jj-jnj-roll-out-pharma-q4-earnings-with-a-beat?cid=CS-ZC-FT-analyst_blog|earnings_preview-722277 Jan 17, 2020 - J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates http://www.zacks.com/stock/news/722255/pharma-stock-roundup-lly-dermira-buyout-offer-pipeline-regulatory-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-722255 Jan 17, 2020 - Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review http://www.zacks.com/stock/news/720677/clovis-rubraca-snda-for-prostate-cancer-gets-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-720677 Jan 16, 2020 - Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA http://www.zacks.com/stock/news/720624/bristol-myers-opdivo-yervoy-sbla-for-nsclc-accepted-by-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-720624 Jan 16, 2020 - The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report? http://www.zacks.com/stock/news/719358/will-merck-mrk-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-719358 Jan 15, 2020 - Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AstraZeneca to End Phase III Study on Fish Oil Heart Drug http://www.zacks.com/stock/news/717304/astrazeneca-to-end-phase-iii-study-on-fish-oil-heart-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-717304 Jan 14, 2020 - AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee
Merck & Co., Inc. (MRK) CEO Ken Frazier Presents Annual J.P. Morgan Healthcare Conference (Transcript) https://seekingalpha.com/article/4316624-merck-co-inc-mrk-ceo-ken-frazier-presents-annual-j-p-morgan-healthcare-conference-transcript?source=feed_sector_transcripts Jan 13, 2020 - Merck & Co., Inc. (NYSE:MRK) Annual J.P. Morgan Healthcare Conference January 13, 2020 7:30 p.m. ET Company Participants Ken Frazier - Chairman and CEO Roger Perlmutter - President of Merck Resear

Pages: 123456789...103

<<<Page 4>